Shares of Bristol-Myers Squibb briefly fell more than 17 percent in opening trade Friday after its cancer drug failed to meet targets in a late-stage study.
Shares of Bristol-Myers Squibb briefly fell more than 17 percent in opening trade Friday after its cancer drug failed to meet targets in a late-stage study.